JPS6334879B2 - - Google Patents
Info
- Publication number
- JPS6334879B2 JPS6334879B2 JP56001586A JP158681A JPS6334879B2 JP S6334879 B2 JPS6334879 B2 JP S6334879B2 JP 56001586 A JP56001586 A JP 56001586A JP 158681 A JP158681 A JP 158681A JP S6334879 B2 JPS6334879 B2 JP S6334879B2
- Authority
- JP
- Japan
- Prior art keywords
- lubomycin
- hydrochloride
- compound
- oxyl
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- 150000007857 hydrazones Chemical class 0.000 claims description 5
- 230000005414 paramagnetic center Effects 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 41
- 241001465754 Metazoa Species 0.000 description 13
- 230000001093 anti-cancer Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 9
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 8
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 229960000975 daunorubicin Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000007093 Leukemia L1210 Diseases 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 229960000641 zorubicin Drugs 0.000 description 5
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010028570 Myelopathy Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000007665 chronic toxicity Effects 0.000 description 3
- 231100000160 chronic toxicity Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000925 erythroid effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical class O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 208000000526 Experimental Leukemia Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 208000008342 Leukemia P388 Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001362 electron spin resonance spectrum Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU802893526A RU977462C (ru) | 1980-03-24 | 1980-03-24 | 13-(1-оксил-2,2,6,6-тетраметилпиперилиденил-4)гидразон рубомицина хлоргидрат с парамагнитным центром, проявляющий противоопухолевую активность, и способ его получения |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56133298A JPS56133298A (en) | 1981-10-19 |
| JPS6334879B2 true JPS6334879B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-07-12 |
Family
ID=20882488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP158681A Granted JPS56133298A (en) | 1980-03-24 | 1981-01-08 | 13-(1-oxyl-2,2,6,6-tetramethylpiperilidenyl- 4)hydrazone lubomycin hydrochloride having paramagnetic core and manufacture |
Country Status (9)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050003008A1 (en) * | 1997-09-23 | 2005-01-06 | Natalya Rapoport | Method of in vivo drug targeting to solid tumors via acoustically triggered drug delivery in polymeric micelles |
| US7910607B2 (en) * | 2006-03-10 | 2011-03-22 | The Trustees Of California State University | Nitroxide free radical synergized antineoplastic agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2235103A1 (en) * | 1973-06-29 | 1975-01-24 | Commissariat Energie Atomique | Marked nitroxide derivatives of saccharides - by reaction of acid nitroxide with halogenated saccharides |
| GB1469430A (en) | 1974-12-24 | 1977-04-06 | Farmaceutici Italia | Daunomycin derivatives |
| US4112217A (en) * | 1977-09-02 | 1978-09-05 | Sri International | Bis-hydrazones of daunomycin and adriamycin |
-
1980
- 1980-03-24 RU SU802893526A patent/RU977462C/ru active
- 1980-10-02 US US06/192,964 patent/US4332934A/en not_active Expired - Lifetime
- 1980-10-02 SE SE8006901A patent/SE449105B/sv not_active IP Right Cessation
- 1980-10-07 GB GB8032334A patent/GB2072658B/en not_active Expired
- 1980-10-07 DE DE3037884A patent/DE3037884C2/de not_active Expired
- 1980-10-07 NL NLAANVRAGE8005543,A patent/NL182882C/xx not_active IP Right Cessation
- 1980-10-22 FR FR8022569A patent/FR2478633A1/fr active Granted
- 1980-10-30 IT IT25669/80A patent/IT1134110B/it active
-
1981
- 1981-01-08 JP JP158681A patent/JPS56133298A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2478633A1 (fr) | 1981-09-25 |
| SE449105B (sv) | 1987-04-06 |
| GB2072658A (en) | 1981-10-07 |
| NL182882B (nl) | 1988-01-04 |
| DE3037884C2 (de) | 1983-12-29 |
| NL182882C (nl) | 1988-06-01 |
| FR2478633B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1983-07-22 |
| IT1134110B (it) | 1986-07-24 |
| US4332934A (en) | 1982-06-01 |
| IT8025669A0 (it) | 1980-10-30 |
| JPS56133298A (en) | 1981-10-19 |
| NL8005543A (nl) | 1981-10-16 |
| GB2072658B (en) | 1983-11-02 |
| SE8006901L (sv) | 1981-09-25 |
| DE3037884A1 (de) | 1981-10-01 |
| RU977462C (ru) | 1995-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6030997A (en) | Acid labile prodrugs | |
| JP3697210B2 (ja) | 二重ジカルボン酸ジアミノプラチン錯体の抗腫瘍誘導体、その調製方法、それを含む薬剤組成物及びその誘導体の適用方法 | |
| JPS595599B2 (ja) | プラチナ有機錯体、その製法および該錯体よりなる悪性腫瘍治療剤 | |
| FR2525225A1 (fr) | Nouveaux derives 4'-iodo de glycosides d'anthracycline et leur emploi comme medicament | |
| US4594238A (en) | Inhibition of undesired effect of platinum compounds | |
| US4581224A (en) | Inhibition of undesired effect of platinum compounds | |
| JPS6334879B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CA1283904C (en) | Liposoluble platinum (ii) complex and preparation thereof | |
| JP4598227B2 (ja) | 放射線および化学療法における感受性増強剤である化合物、並びにそれらの製造方法および使用 | |
| US6197809B1 (en) | Compounds for the treatment of cancer | |
| WO2000042832A2 (en) | New compounds for the treatment of cancer | |
| US5710179A (en) | Antitumor agent | |
| DE69132392T2 (de) | Pharmazeutische zusammensetzungen von gallium-komplexen von 3-hydroxy-4-pyronen | |
| EP0128670A1 (en) | 4-Demethoxy-3'-deamino-3'(4-morpholinyl) derivatives of anthracycline anticancer antibiotics | |
| EP1678189A2 (de) | Verfahren zur herstellung von trans- oder cis-diammoniumdichlorodihydroxoplatin (iv)-salzen und -derivaten und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen | |
| RU2292209C2 (ru) | Противоопухолевое средство для перорального применения и способ его получения | |
| EP0583572B1 (en) | (S)-2,3-Dihydropolyprenols and, (S)-2,3-dihydropolyprenyl monophosphates, method of preparation and use in inhibiting the metastasis of cancers | |
| AU8780698A (en) | 13-deoxyanthracycline derivatives and processes for preparing them | |
| JPH01153694A (ja) | 新規４‐デメトキシアントラサイクリン誘導体 | |
| CA3183033A1 (en) | Methods for treating cancer using a modified monosaccharide compound | |
| JPS6125707B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| KR0142228B1 (ko) | 신규 안트라사이클린 글리코시드유도체 및 그 제조방법 | |
| GB2035082A (en) | Anti-tumor compositions comprising saponins | |
| FR2558469A1 (fr) | Nouveaux composes de coordination du platine, leurs procedes de fabrication et leur utilisation comme medicaments | |
| EP0410366A2 (de) | Anthracyclin-Derivate |